Opto Circuits India : FREEWAY¬ COATED SHUNT BALLOON CATHETER

·--

GIN : L85110KA1992PLC013223

OPTO CIRCUITS (INDIA) LIMITED. ,rEci

September 16, 2016.

The Manager

Department of Corporate Services Bombay Stock Exchange Ltd

PJ Towers, Dalal Street MUMBAI - 400 001

The Manager

National Stock Exchange of India Ltd Exchange Plaza

Bandra Kurla Complex

Bandra (E), MUMBAI - 400 051

Dear Sir,

Subject: Press Release.

Please find enclosed the press release issued by Opto Circuits (India) Limited, for your kind information & records.

Kindly acknowledge the receipt. Thanking you,

Yours faithfully,

For Opto Circuits (Ind· ) Limited.,

ecr ary

Encl: a/a.

Plot No. 83, First Floor. Electronics City. Bangalore - 560 100.

Phone : [phone]-42 Fax : [phone]

E-mail : [e-mail], [e-mail] Web : www.optocircuits.com

Press Release

Opto Circuits's wholly owned subsidiary, Eurocor GmbH, enters the Global Market with their FREEWAY COATED SHUNT BALLOON CATHETER.

High pressure balloon is recommended for the treatment of AV fistulas and shunt graf ts as it

reduces re-intervention and preserves future treatment options.

Eurocor, a global leader in medical DEB-technology, services and solutions, today announced that the FREEWAY™ - SHUNT BALLOON CATHETER (DEB) has been placed in the market for arteriovenous (AV) access to help patients with end-stage renal disease.

Following the 1st release on the launch of AV Fistula balloon, we are glad to announce that first 500 units had been manufactured and international shipment against orders been executed. The feedback from the physicians on the usage is very positive and we received strong demand from different markets.

The balloon is indicated for Patients who undergo dialysis as they suffer from end stage renal failure. Stenosis and subsequent restenosis of the dialysis shunt graft is a common complication. The treatment of this stenosis is mandatory to protect AV fistulas and shunt grafts from early restenosis

FREEWAY™ - SHUNT DEB protects AV fistulas and shunt grafts from early restenosis and is a clinical proven therapeutically effective option for AV shunt patients. A feasibility study presented at LINC 2015, showed a low re-intervention rate of 11% at follow up.

"We are thrilled to promote our 3,d generation catheters for treatment of AV Fistula through our existing / new distributors and showcase our product in leading hospitals in major markets and regions around the world", says CEO of Eurocor GmbH, Lalit Mamtani

About FREEWAyrM

Eurocor's drug-eluting technology PTA balloon FREEWAY has been developed as an alternative to the limitations of existing therapeutic to PAD e.g. restenosis after POBA or stenting. The product provides excellent crossability, trackability and pushability and can be used where the use of other therapies is limited by the occurrence of high restenosis rates, anatomical challenges and stent fractures.

The coating makes the difference - FREEWAY uses a proprietary homogenous coating

Eurocor's DEB technology utilises a homogenous drug coating, which is released when the balloon is expanded. This inhibits the proliferation of smooth muscle cells, and may prevent restenosis by disturbing microtubule formation and thereby inhibiting cell division and migration. Paclitaxel is applied in a final concentration of 3 µg/mm2 to the surface of the balloon.

FREEWAY™ features

• Clinically proven robust coating, with no drug loss on the way to target.

• Balloon lengths of 20 - 150 mm for 0 2.0-8.0 mm with different shaft lengths

• Excellent catheter flexibility with tapered, hydrophilic shafts and low tip entry profiles

Media Contact Eurocor GmbH Katja Hausner

Phone: [phone]

Email: pressoff [e-mail]

About Eurocor: -End-

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent teclmologies and special cardiovascular and endovascular devices, manufactured in Bonn. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® - with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group.

For more information, please visit eurocor.de andoptocircuits.com.